Bradley J. Monk, MD, FACOG, FACS, at GOG Foundation, HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, Arizona and global primary investigator of the ATHENA trial. In this video, he speaks about Clovis Oncology"™s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival In First-Line Maintenance Treatment In Women With Ovarian Cancer Regardless Of Their Biomarker Status In Phase 3 ATHENA-MONO Trial.
This is a Phase 3 randomized, global, double-blind, dual placebo-controlled, 4-arm research investigating rucaparib plus nivolumab as maintenance treatment in patients with newly diagnosed ovarian cancer who have responded to front-line treatment. The homologous recombination (HR) status of tumor samples will be used to assess therapy response.